All News
Filter News
Found 17,395 articles
-
Weight-Loss Drug Startup Metsera Launches with $290M, Looks to Tap Lucrative Obesity Market
4/18/2024
The clinical-stage biotech emerged from stealth on Thursday with several oral and injectable candidates, including a GLP-1 receptor agonist in Phase I trials, in an effort to challenge Novo Nordisk and Eli Lilly. -
T-cell Therapy Market Size, Share & Analysis Report, 2024-2033
4/18/2024
According to Nova One Advisor, the global T-cell therapy market size was valued at USD 3.85 billion in 2023
-
Gene Therapy Market Size Poised to Surge USD 52.40 Billion by 2033
4/18/2024
The global gene therapy market size was valued at USD 8.75 billion in 2023 and is poised to grow from USD 10.47 billion in 2024
-
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
4/18/2024
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open.
-
As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.
-
RNAi Therapeutics Market Size to Climb USD 4.28 Billion by 2033
4/17/2024
The RNAi therapeutics market size reached a value of USD 1.11 billion by 2023 is expected to surge USD 4.28 billion by 2033, projections indicate an impressive CAGR of 14.9% over the forecast period 2023 – 2033, a study by Towards Healthcare.
-
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis
4/17/2024
Novartis announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta® treatment for up to six years in recently diagnosed – defined as starting treatment within three years of initial diagnosis – treatment-naïve people living with relapsing multiple sclerosis.
-
Novartis on Monday shared late-stage data for its potential multibillion-dollar drug Fabhalta, in what the company contends is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in IgA nephropathy patients.
-
Oncology Market Size to Exceed USD 521.60 Billion by 2033 | CAGR 8.9%
4/16/2024
The global oncology market size was valued at USD 222.36 billion in 2023 and is poised to grow from USD 242.15 billion in 2024
-
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
4/16/2024
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases.
-
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market
4/16/2024
In October of 2023, the US FDA approved Novartis’ intravenous formulation of Cosentyx for the treatment of psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.
-
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
4/16/2024
BioArctic AB hereby announces that the Nomination Committee for BioArctic AB presents the following proposals regarding the resolution on the number of board members and the election of board members and Chairperson of the Board at the Annual General Meeting on May 22, 2024.
-
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
4/16/2024
Ocular Therapeutix, Inc. announced that it has strengthened its clinical development organization with the appointment of Nadia K. Waheed, MD, MPH, as Chief Medical Officer; Peter K. Kaiser, MD as Chief Development Officer; Andrea Gibson, Ph.D., as Vice President, Medical Collaborations; and Namrata Saroj, OD, as Development Strategy Consultant.
-
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
4/16/2024
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc., a wholly owned subsidiary of Eli Lilly and Company.
-
Active Pharmaceutical Ingredients Market Size to Increase USD 416.15 Billion By 2033
4/15/2024
The global active pharmaceutical ingredients market size was evaluated at USD 237.48 billion in 2023 and it is expected to increase around USD 416.15 billion by 2033 with a CAGR of 5.77% from 2024 to 2033.
-
Pharmacogenomics Market Size is Forecasted to Worth USD 35.67 Billion by 2032
4/15/2024
The global pharmacogenomics market size was reached at USD 15 billion in 2022 and is forecasted to be worth over USD 35.67 billion by 2032 with a CAGR of 9.1% from 2023 to 2032.
-
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
4/15/2024
Novartis today presented results from a pre-specified interim analysis of the Phase III APPLAUSE-IgAN study of Fabhalta® (iptacopan), an investigational Factor B inhibitor of the alternative complement pathway, in patients with IgA nephropathy (IgAN)1.
-
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
4/15/2024
Ocular Therapeutix, Inc. announced that Executive Chairman, Pravin U. Dugel, MD, is assuming the roles of President and Chief Executive Officer, and that Antony Mattessich is stepping down as President and CEO, effective immediately.
-
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
4/15/2024
Applied Therapeutics, Inc. announced the appointment of Dale Hooks as Chief Commercial Officer, replacing Adam Hansard, effective immediately.
-
Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors
4/15/2024
Neurvati Neurosciences today announced the appointment of Dr. Deborah Dunsire as a new member and the new chair of the company's board of directors.